A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses

• DOI: 10.1128/jvi.02482-20
• Publication Date: 2021-03-25T13:16:07Z
• Authors: Clayton J. Wollner; Michelle Richner; Mariah A. Hassert; Amelia K. Pinto; James D. Brien; Justin M. Richner
• Keywords: 0303 health sciences; T-Lymphocytes; Dengue Vaccines; Adaptive Immunity; Cross Reactions; Dengue Virus; Antibodies, Viral; Serogroup; Antibodies, Neutralizing; Antibody-Dependent Enhancement; Cell Line; Immunity, Humoral; 3. Good health; Dengue; Mice, Inbred C57BL; Mice; 03 medical and health sciences; Liposomes; Animals; Nanoparticles; RNA, Viral; RNA, Messenger; Immunization Schedule

With 400 million worldwide infections each year, dengue is the most common vector-borne viral disease. Forty percent of the world's population is at risk, with dengue experiencing consistent geographic spread over the years.